Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer

References

• Li L, Xu MZ, Wang L, et al. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharmacol Sci. 2020;24(24):12929–12937. doi:10.26355/eurrev_202012_24196
   PubMed Web of Science ®Google Scholar
• Jiang J, Li S, Shan X. Preclinical safety profile of Disitamab Vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30–37. doi:10.1016/j.toxlet.2019.12.027
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Y, Gong J. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913–925. doi:10.1007/s10120-021-01168-7
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Zheng Y, Fang W, Mao C. Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a Phase II study. Cancer Chemother Pharmacol. 2014;74(3):503–509. doi:10.1007/s00280-014-2537-2
   PubMed Web of Science ®Google Scholar
• Zhong H, Zhang Y, Ma S. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(10):1013–1018. doi:10.1097/CAD.0b013e328314b5ab
   PubMed Web of Science ®Google Scholar
• Sun Q, Hang M, Xu W. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol. 2009;39(12):791–796. doi:10.1093/jjco/hyp116
   PubMed Web of Science ®Google Scholar
• Lam JYC, Choo SP, Tai DW. What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. Asia Pac J Clin Oncol. 2020;16(1):23–27. doi:10.1111/ajco.13285
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Randomized XJ. Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.5995
   PubMed Web of Science ®Google Scholar
• Chan WL, Lam KO, So TH. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990. doi:10.1177/1758835919859990
   Web of Science ®Google Scholar
• Palle J. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: current Knowledge and Future Perspectives. Drugs. 2020;80(4):401–415. doi:10.1007/s40265-020-01272-5
   PubMed Web of Science ®Google Scholar
• Hsu A, Chudasama R, Almhanna K. Targeted therapies for gastroesophageal cancers. Ann Transl Med. 2020;8(17):1104. doi:10.21037/atm-20-3265
   PubMed Web of Science ®Google Scholar
• Wang H, Guo W, Hu Y. Superiority of the 8th edition of the TNM staging system for predicting overall survival in gastric cancer: comparative analysis of the 7th and 8th editions in a monoinstitutional cohort. Mol Clin Oncol. 2018;9(4):423–431. doi:10.3892/mco.2018.1683
   PubMed Web of Science ®Google Scholar
• Zhao L, Li J, Bai C. Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: a Real-World Study in China. Front Oncol. 2019;9:1155. doi:10.3389/fonc.2019.01155
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e18001. doi:10.1001/jamaoncol.2018.0013
   Web of Science ®Google Scholar
• Peng Z, Wei J, Wang F. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2021;27(11):3069–3078. doi:10.1158/1078-0432.CCR-20-4691
   PubMed Web of Science ®Google Scholar
• Gong Y, Wang P, Zhu Z. Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: a Meta-Analysis. J Surg Res. 2020;245:234–243. doi:10.1016/j.jss.2019.07.044
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712. doi:10.1126/science.2470152
   PubMed Web of Science ®Google Scholar
• Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40:770–780. doi:10.1016/j.ctrv.2014.02.008
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/JCO.2013.50.9984
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial.lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Mitani S, Kawakami H. Emerging targeted therapies for HER2 positive gastric cancer that can overcome trastuzumab resistance. Cancers. 2020;12(2):400. doi:10.3390/cancers12020400
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48. doi:10.1038/s41571-019-0268-3
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419–2430. doi:10.1056/NEJMoa2004413
   PubMed Web of Science ®Google Scholar
• Sheng X, Yan X, Wang L. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021;27(1):43–51. doi:10.1158/1078-0432.CCR-20-2488
   PubMed Web of Science ®Google Scholar